Category Archives: John Klein

Enterprise Performance Management Beneficial for Businesses

John Klein draws upon more than four decades of leadership experience in the pharmaceutical sector to his position as chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to this role, John Klein serves as the chairman and CEO of Bilogix, LLC, which provides unique enterprise performance management (EPM) solutions to customers in line with their corporate strategy.

EPM services can enhance business strategy and processes such as budgeting and financial modeling and analysis. EPM is a complex methodology that involves a number of aspects, such as the creation of an enterprise strategy. Designed to help companies seeking to improve their performance, EPM requires a solid strategic plan as its basis. Through EPM, the various aspects of the strategic plan are deployed throughout an organization. Another area of EPM entails mapping an organization. A blueprint is created outlining how the work will be accomplished and what the outputs will be.

Mapping an organization aids in the identification of areas in need of improvement and key performance indicators (KPIs). An additional aspect of EPM involves developing scorecards. Business scorecards can provide managers with quick access to critical information. The scorecards show metrics on KPIs that can aid in managerial decision-making.

The Importance of a Clearly Defined EPM Project Scope

Based in Alpine, NJ, John Klein is an experienced pharmaceutical executive who has served as the chairman of Cambridge Therapeutics since 2011. Additionally, John Klein is the chairman and CEO of Bilogix, LLC, which operates in the enterprise performance management (EPM) space.

A set of processes and applications that help analyze and predict the performance of an organization, EPM can significantly improve actions and outcomes relating to business strategy, enterprise planning and budgeting, financial modeling, and business reporting. However, in order to increase the likelihood of the success of an EPM project, managers must clearly identify the scope of the project, including its goals and objectives.

All relevant stakeholders should be consulted in determining the work required to achieve the project’s goals. Moreover, it is vital to define what won’t be accomplished during the project to ensure all involved are completing tasks in line with its primary purpose. Setting the project’s scope will also help define the tools required to outline project activities, establish project phases, assign resources, and estimate the budget required to complete the project. Working with stakeholders, managers should then establish a list of desired goals, such as improved performance times or enhanced process efficiencies, which will be used to gauge the success of the project.

Enterprise Performance Management Increases Operational Efficiency

Possessing more than two decades of experience in pharmaceutical manufacturing, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. Aside from steering Cambridge Therapeutics, John Klein directs the business-development firm Bilogix.

Providing services in the growing field of enterprise performance management (EPM), Bilogix employs experienced consultants who assist businesses in conducting strategic analyses of their business intelligence (BI) and overall operational efficiency to perform better in a constantly-evolving marketplace.

EPM consultants might also evaluate the company’s expenditures and how much value that spending contributes to or review return on investment (ROI) data. The ROI process provides measurable values for determining an investment’s efficiency or making comparisons between different ones. Additionally, it assesses the return on specific investments in relation to its cost. These practices help to better inform executive management on how to create the best solutions for increasing performance and generating more profit for the enterprise.

How Does the Enterprise Performance Management Process Work?

Serving as the chairman of Cambridge Therapeutics in Alpine, NJ, John Klein has more than two decades of executive experience in the healthcare and pharmaceutical industries. In addition to leading Cambridge Therapeutics, John Klein recently founded a new firm in Alpine, NJ, called Bilogix.

A company that provides enterprise performance management (EPM) services, Bilogix helps business clients attain maximum efficiency and boost profits. Using a complex approach to operations analysis, the EPM team reviews details such as budgets, sales forecasts and reports, and accounting information to determine ways in which a firm can enhance its performance and eliminate the waste of resources. The goal of EPM is to ensure that businesses have the data and knowledge they need to make optimal operational decisions that promote continued growth and long-term sustainability.

A large part of the EPM analysis deals with a company’s technological capacity. As cloud computing becomes more pervasive, smart institution leaders are adopting this and other advanced technologies to increase their flexibility and stay relevant.

Home Health Care Agencies Face Nurse Shortage

An accomplished pharmaceutical executive with more than 20 years of industry experience, John Klein serves as the chairman of the Alpine, NJ-based Cambridge Therapeutics. In addition to his responsibilities at Cambridge Therapeutics, John Klein actively follows health-related news affecting NJ.

Home healthcare agencies in NJ recently warned of a future shortage of private duty nurses (PDNs) in the state. Pointing to lower-than-desired Medicaid reimbursement rates, agency representative said that they are experiencing difficulties recruiting qualified nurses for home-based services. PDNs provide around-the-clock care for medically complex patients in their homes, sometimes tending to individuals who are cognitively impaired or born with congenital defects.

Licensed as either a registered nurse or a licensed practical nurse, PDNs are paid through Medicaid reimbursements, making it hard for them to earn as much as their hospital-based counterparts. More than a decade has passed since the last Medicaid-reimbursement increase.

According to an internal study by BAYADA Home Health Care, the home healthcare industry attracts only 17 percent of registered nurses and 40 percent of licensed practical nurses, leaving many patients without the nursing care they need.

Bergen New Bridge and Horizon BCBS Announce Partnership

The recipient of a master of business administration from Roosevelt University, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to guiding Cambridge Therapeutics’ strategic direction, John Klein closely follows health-related developments in NJ.

Recently, the state’s largest hospital, Bergen New Bridge Medical Center, and NJ’s biggest insurance company, Horizon Blue Cross Blue Shield (Horizon BCBS), announced the formation of a new partnership. In July 2019, NJ Governor Phil Murphy joined representatives from Bergen New Bridge, Horizon BCBS, and Bergen County to celebrate the alliance, which is expected to increase access to multiple healthcare services for local residents.

The new agreement will enable Bergen New Bridge to accept insurance for approximately 230,000 Horizon BCBS members in Bergen County and others whose plans were previously denied. Governor Murphy praised the cooperation, stating that expanding access to the addiction-rehabilitation program and other means of aid at the hospital will help fill treatment gaps in the state.

Judith Persichilli Appointed to Lead NJ Health Department

A distinguished pharmaceutical executive with almost 30 years of industry experience, John Klein serves as the chairman of Cambridge Therapeutics in Alpine, NJ. In addition to guiding the business development of Cambridge Therapeutics, John Klein actively follows NJ news in the areas of health care policy.

New Jersey Governor Phil Murphy recently appointed Judith Persichilli to serve as the new head of the NJ Department of Health beginning in July 2019. A well-known hospital executive and registered nurse, Ms. Persichilli replaces Dr. Shereef Elnahal, who took a chief executive position with Newark’s University Hospital. The appointment awaits confirmation from the state’s Senate.

A resident of Pennington, Ms. Persichilli formerly served as the director of Trinity Health before spending much of 2018 at University Hospital, where she worked to study and reform the struggling facility. Nursing and hospital leaders, as well as the New Jersey Health Care Quality Institute that Ms. Persichilli helped establish, applauded her appointment. She is known for not only her experience as a clinician and administrative expertise in the health care sector, but also her strong leadership skills.